PL2794628T3 - 4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV - Google Patents

4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV

Info

Publication number
PL2794628T3
PL2794628T3 PL12808791T PL12808791T PL2794628T3 PL 2794628 T3 PL2794628 T3 PL 2794628T3 PL 12808791 T PL12808791 T PL 12808791T PL 12808791 T PL12808791 T PL 12808791T PL 2794628 T3 PL2794628 T3 PL 2794628T3
Authority
PL
Poland
Prior art keywords
azido
inhibitors
hcv rna
fluoro substituted
rna replication
Prior art date
Application number
PL12808791T
Other languages
English (en)
Polish (pl)
Inventor
Mark Smith
Francisco Xavier Talamas
Jing Zhang
Zhuming Zhang
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of PL2794628T3 publication Critical patent/PL2794628T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL12808791T 2011-12-20 2012-12-17 4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV PL2794628T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577712P 2011-12-20 2011-12-20

Publications (1)

Publication Number Publication Date
PL2794628T3 true PL2794628T3 (pl) 2017-09-29

Family

ID=47469968

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12808791T PL2794628T3 (pl) 2011-12-20 2012-12-17 4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV

Country Status (31)

Country Link
US (1) US9708357B2 (h)
EP (1) EP2794628B1 (h)
JP (1) JP6118336B2 (h)
KR (1) KR101687084B1 (h)
CN (2) CN108409820A (h)
AU (1) AU2012357986B2 (h)
BR (1) BR112014015066A2 (h)
CA (1) CA2869317C (h)
CL (1) CL2014001599A1 (h)
CO (1) CO6990719A2 (h)
CR (1) CR20140255A (h)
CY (1) CY1119015T1 (h)
DK (1) DK2794628T3 (h)
EA (1) EA024847B1 (h)
ES (1) ES2626484T3 (h)
HK (1) HK1200835A1 (h)
HU (1) HUE033332T2 (h)
IL (1) IL232843B (h)
IN (1) IN2014CN04530A (h)
LT (1) LT2794628T (h)
MA (1) MA35749B1 (h)
MX (1) MX350810B (h)
PE (1) PE20141599A1 (h)
PH (1) PH12014501283A1 (h)
PL (1) PL2794628T3 (h)
PT (1) PT2794628T (h)
SG (1) SG11201403086YA (h)
SI (1) SI2794628T1 (h)
UA (1) UA110428C2 (h)
WO (1) WO2013092447A1 (h)
ZA (1) ZA201404444B (h)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676797B2 (en) * 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
KR101687084B1 (ko) 2011-12-20 2016-12-15 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
KR20150014457A (ko) 2012-05-25 2015-02-06 얀센 알 앤드 디 아일랜드 우라실 스피로옥세탄 뉴클레오시드
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
WO2014058801A1 (en) 2012-10-08 2014-04-17 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
MA38678A1 (fr) * 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2020007070A1 (zh) * 2018-07-02 2020-01-09 河南真实生物科技有限公司 4'-取代核苷的晶型、制备和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (en) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Antibacterial compounds, use and preparation thereof
JPS6422823A (en) * 1987-07-17 1989-01-25 Asahi Glass Co Ltd Antiulcer agent
US5449664A (en) 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
JP4327910B2 (ja) 1997-03-14 2009-09-09 バーテックス ファーマシューティカルズ インコーポレイテッド Impdh酵素のインヒビター
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
US6143715A (en) 1997-08-11 2000-11-07 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
EP1100763B8 (en) 1998-07-27 2005-08-17 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
CA2341970A1 (en) 1998-08-21 2000-03-02 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
CA2343522A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
HUP0201214A3 (en) 1999-03-19 2002-11-28 Vertex Pharmaceuticals Inc Cam Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Flavivirus感染の処置または予防のための化合物および方法
EP2206709A3 (en) 2001-06-11 2011-06-29 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としてのアシルジヒドロピロール誘導体
DE60221875T2 (de) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren
CA2488534A1 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AU2004233989A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
AU2004235848B2 (en) 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
BRPI0506945A (pt) 2004-01-30 2007-06-12 Medivir Ab inibidores de serina protease ns-3 de hcv
CA2590115A1 (en) 2004-12-10 2006-06-15 Emory University 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
AU2010203416C1 (en) * 2009-01-09 2013-07-25 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
CN102686599B (zh) * 2009-09-29 2016-10-05 杨森产品有限公司 核苷的氨基磷酸酯衍生物
JP5937073B2 (ja) 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
PH12013500629A1 (en) 2010-09-22 2019-10-11 Alios Biopharma Inc Substituted nucleotide analogs
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
KR101687084B1 (ko) 2011-12-20 2016-12-15 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체

Also Published As

Publication number Publication date
CA2869317C (en) 2016-05-17
UA110428C2 (uk) 2015-12-25
IL232843A0 (en) 2014-07-31
KR20140108303A (ko) 2014-09-05
MX350810B (es) 2017-09-20
CN104011060A (zh) 2014-08-27
CR20140255A (es) 2014-08-20
PT2794628T (pt) 2017-07-05
CL2014001599A1 (es) 2014-11-03
LT2794628T (lt) 2017-07-10
HK1199037A1 (en) 2015-06-19
ES2626484T3 (es) 2017-07-25
CO6990719A2 (es) 2014-07-10
AU2012357986A1 (en) 2014-06-19
AU2012357986B2 (en) 2017-02-02
HUE033332T2 (en) 2017-11-28
NZ625844A (en) 2016-08-26
US20140369959A1 (en) 2014-12-18
JP6118336B2 (ja) 2017-04-19
CY1119015T1 (el) 2018-01-10
SI2794628T1 (sl) 2017-07-31
BR112014015066A2 (pt) 2017-06-13
CA2869317A1 (en) 2013-06-27
MA35749B1 (fr) 2014-12-01
IN2014CN04530A (h) 2015-09-11
EA201491180A1 (ru) 2014-11-28
ZA201404444B (en) 2015-08-26
HK1200835A1 (en) 2015-08-14
EP2794628B1 (en) 2017-03-29
EA024847B1 (ru) 2016-10-31
EP2794628A1 (en) 2014-10-29
SG11201403086YA (en) 2014-07-30
PE20141599A1 (es) 2014-10-30
CN108409820A (zh) 2018-08-17
WO2013092447A1 (en) 2013-06-27
JP2015500851A (ja) 2015-01-08
KR101687084B1 (ko) 2016-12-15
MX2014007028A (es) 2014-09-16
PH12014501283A1 (en) 2014-09-08
DK2794628T3 (en) 2017-07-10
IL232843B (en) 2018-02-28
US9708357B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
PL2794628T3 (pl) 4'-azydo-3'-fluoro podstawione pochodne nukleozydów jako inhibitory replikacji RNA HCV
LT2794629T (lt) 2`,4`-difluor-2`-metilu pakeistieji nukleozidų dariniai, kaip hcv rnr replikacijos inhibitoriai
HUS2100048I1 (hu) Adenin-származék mint PI3K inhibitor
EP2542074A4 (en) PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
HUE059432T2 (hu) Módszerek és kompozíciók a kras aszimmetrikus kettõs szálú RNS által történõ specifikus gátlására
SG10201602369PA (en) Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
ZA201107618B (en) Theino [2,3-b] pyridine derivatives as viral replication inhibitors
DK2681227T3 (da) Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
AP2014007796A0 (en) Substituted nucleosides, nucleotides and analogs thereof
IL212786A0 (en) New 4 - amino - 4 - oxobutanoyl peptides as inhibitors of viral replication
ZA201309150B (en) Derivatives of 1-phenyl-2-pyridinyl- alkyl alcohols as phosphodiesterase inhibitors
PT3587579T (pt) Métodos e composições para a inibição específica de beta-catenina por rna de filamento duplo
ZA201306416B (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2012145254A9 (en) Methods of using inhibitors of rorϒt to treat disease
EP2667872A2 (en) Small molecule rnase inhibitors and methods of use
ZA201404711B (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
RS56101B1 (sr) 4'-azido-3'-fluoro supstituisani derivati nukleozida kao inhibitori hcv rnk replikacije
WO2013033705A3 (en) Non-natural nucleosides as theranostic agents
TH1401003558A (th) อนุพันธ์นิวคลีโอไซด์ที่ถูกแทนที่แบบ 4'-อะซิโด,3'-ฟลูออโรในฐานะที่เป็นตัวยับยั้งการถ่ายแบบ rna ของ hcv
AU2013359069A1 (en) Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
HK1192754A (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ZA201104381B (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication